What does remission mean for Triple-Negative Breast Cancer and how is it monitored

Understanding Remission in Triple-Negative Breast Cancer

What Remission Means

Remission in triple-negative breast cancer (TNBC) refers to a state where there is no evidence of disease (NED) or significantly reduced disease activity. For TNBC specifically, remission typically means:

• Complete remission: No detectable cancer cells on imaging or blood tests
• Partial remission: Significant reduction in tumor size or cancer markers, but some disease may still be present

It's important to understand that remission is not the same as cure. Remission means the cancer is currently controlled, but ongoing monitoring is essential because TNBC can recur, particularly in the first 2-3 years after treatment.

---

How Remission is Monitored

According to the webinar content on personalized cancer treatment monitoring, remission assessment involves multiple layers of evaluation:

1. Circulating Tumor Cells (CTCs) - Blood-Based Monitoring

One emerging approach discussed in the CancerPatientLab webinars involves monitoring circulating tumor cells in the bloodstream:

• Target levels: Remission is generally considered when CTC counts drop to 0-1 cells per sample (very low risk level)
• Phenotype markers matter: Simply looking at CTC numbers alone can be misleading. Doctors also examine tumor stem cell markers (phenotype markers) because these cancer stem cells are the ones that drive disease progression and are often the last to disappear
• Why this matters: You can have low CTC numbers but still have active cancer stem cells present, which means treatment isn't truly complete

As explained in the webinar: "If you don't look at that phenotype markers, and you just rely on the CTC number, sometimes that's misleading...the subpopulation which the ones with the tumor stem cell markers, they're the ones that drive the disease."

2. Standard Imaging and Clinical Assessment

Your oncology team will use:

• CT scans or MRI: Typically performed every 3-6 months initially, then less frequently as time passes
• Physical exams: Regular clinical evaluation by your oncologist
• Tumor markers: Blood tests measuring cancer-related proteins (though these are less specific for TNBC than for hormone-receptor positive breast cancers)

3. Ongoing Surveillance Schedule

According to NCCN Guidelines for breast cancer follow-up:

• First 2-3 years: More frequent monitoring (every 3-6 months) since TNBC has higher recurrence risk early on
• Years 3-5: Typically every 6-12 months
• After 5 years: Annual surveillance, though this varies based on individual risk factors

---

Why TNBC Requires Careful Monitoring

Triple-negative breast cancer is monitored more intensively than other breast cancer types because:

1. Higher recurrence risk: TNBC tends to recur earlier and more frequently than hormone-receptor positive cancers
2. Limited targeted options: Unlike ER+ or HER2+ cancers, TNBC doesn't respond to hormone therapy or HER2-targeted drugs, making prevention of recurrence critical
3. Aggressive biology: TNBC typically grows faster, requiring vigilant surveillance

---

Questions to Ask Your Oncology Team

To ensure comprehensive remission monitoring for your TNBC:

1. "What specific tests will you use to monitor my remission status, and how often?" (imaging, blood tests, CTCs, etc.)
2. "What are the target values or findings that indicate I'm in remission?"
3. "How long will I need intensive monitoring, and when does the schedule change?"
4. "What symptoms or changes should I report immediately between appointments?"
5. "Are there any emerging blood-based tests (like CTC monitoring) that might be appropriate for my case?"
6. "What is my individual recurrence risk, and does that affect my monitoring plan?"

---

Important Context

The webinar discussions on personalized monitoring emphasize that remission assessment is becoming more sophisticated. While traditional imaging remains the standard of care, emerging liquid biopsy approaches (blood tests) may provide earlier detection of recurrence. However, your oncologist will determine which monitoring strategy is most appropriate for your specific situation based on your treatment response and individual risk factors.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.